PREVIDA- IMPACT OF VORTIOXETINE ON MAJOR DEPRESSIVE DISORDER AND PERCEIVED COGNITIVE DYSFUNCTION- A MULTICENTER STUDY

  • Ali Ahsan Mufti
  • Huma mughal Consultant Clinical Psychologist Department of Psychiatry Hayatabad Medical Complex, Peshawar
  • Mukhtar Ul Haq Azeemi Associate Professor,Department Of Psychiatry Medical Teaching Institute Lady Reading Hospital Peshawar
  • Muhammad Asif Kamal Associate Professor, Department of Psychiatry, Gajju Khan Medical College,Swabi
  • Fazal e Rabbani Assistant Professor, Chairman & HOD Psychiatrry, Lady Reading Hospital Peshawar
  • Khalid Attaullah Mufti Professor Of Psychiatry, Chief Executive & Horizon NGO, Ibadat Hospital, Peshawar
  • Syed Muhammad Sultan Professor Of Psychiatry, Chief Executive, Syed Psychiatric Clinic, Peshawar
  • Bashir Ahmad Professor Of Psychiatry Department Of Psychiatry Khyber Teaching Hospital, Peshawar
  • Zainab Nawaz Senior Registrar Gajju Khan Medical College Swabi
  • Adil Afridi Consultant Psychiatrist Gajju Khan Medical College Swabi
  • Fatima Amir Khan Assistant ProfessorConsultant PsychiatristDepartment of  Behavioral Sciences/PsychiatryWah Medical CollegePOF College, Wah Cant
  • Muhammmad Fahim Qasim Associate Professor Benazir Bhutto Shaheed Medical College, Mirpur, Azad Jammu Kashmir
  • Shakil Asif Associate Professor Benazir Bhutto Shaheed Medical College, Mirpur, Azad Jammu Kashmir
  • Syed Usman Hamdani Clinical Lecturer Department of Primary Care and Mental Health, University of Liverpool, UK
  • Ayesha Minhas Associate Professor Of Psychiatry Shifa Tamir E Millat University Global Institute Of Human Development
  • FAREED ASLAM MINHAS Director, The Tree House Psychiatry Clinic, Rawalpindi Pakistan
Keywords: Major depressive disorder in pakistan;, Cognitive dysfunction in Pakistan:, Vortioxetine in pakistan:, Previda in Pakistan, Depression severity

Abstract

Exploring Cognitive Dysfunction and Treatment Efficacy of Vortioxetine in Major Depressive Disorder: Previda in Pakistan

 

 

 

Objective:

To investigate the prevalence of cognitive Dysfunction in major depressive disorder (MDD) and evaluate the efficacy of vortioxetine in treating both depressive symptoms and cognitive dysfunction.

 

Design:

 Prospective, Cross-sectional and multicentered

 

Place & Duration of Study:

The study was conducted in 16 Psychiatric outpatients Departments in Pakistan, for a period of 12 weeks.

 

Patients & Methods:

A total of 498 participants with diagnosis of major depression disorder were included in the study. The severity of depression  and cognitive dysfunction were measured. The Psychiatrists prescribed vortioxetine to participants after assessments  by Clinical Global Impression-Severity scale (CGI-S), the Patient Health Questionnaire-9 (PHQ-9).and Perceived Deficits Questionnaire (PDQ). The variables were again assessed after treatment initiation  at 1 week (+/– 3 days), 1 month ( +/– 7 days) and 3 months(+/– 14 days).

 

Results

Upon completion of a 12 week treatment regimen involving vortioxetine subjects with MDD showced notable improvements in mean PHQ 9 and PDQ scores. This signifies vortioxetines efficiency in alleviating depressive symptoms alongside cognitive deficits within individuals diagnosed with MDD. There was positive correlation noted  between PHQ 9 and PDQ scores, demonstrating a close association linking depressive symptoms to cognitive dysfunction.

 

Conclusions

The study findings shows the effectiveness of vortioxetine in addressing cognitive deficits in patients diagnosed with MDD while also improving depressive symptoms. These results highlight the potential of vortioxetine as a valuable treatment alternative for individuals facing cognitive impairment alongside their MDD diagnosis. Further research is necessary to verify these results and consider their applicability to diverse populations.

 

Downloads

Download data is not yet available.

Author Biographies

Fatima Amir Khan, Assistant ProfessorConsultant PsychiatristDepartment of  Behavioral Sciences/PsychiatryWah Medical CollegePOF College, Wah Cant
 
FAREED ASLAM MINHAS , Director, The Tree House Psychiatry Clinic, Rawalpindi Pakistan

      

References

1. Alvarez E, Perez V, Dragheim M, Loft H, Artigas F (2012) A double-blind, randomized,
2. Placebo-controlled, active-reference study of Lu AA21004 in patients with major
3. Depressive disorder (MDD). Int J Neuropsychopharmacol 15:589–600.
4. Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H,
5. Nielsen SM, Hogg S, Mørk A, Stensbøl TB (2011) Discovery of 1-(2-(2,4-)
6. Dimethylphenylsulfanyl) phenyl piperazine (Lu AA21004): a novel multimodal compound
7. For the treatment of major depressive disorder. J Med Chem 54:3206–3221.
8. Baune BT, Miller R, McAfoose J, Johnson M, Quirk F, Mitchel D (2010) The role of Cognitive Impairment in general functioning in major depression. Psychiatry Res 2010 Apr 30;176(2-3):183-9. doi:


9. -Buist-Bouwman MA, Ormel J, de Graaf R, de Jonge P, van Sonderen E, Alonso J, Bruffaerts R,
10. Vollebergh WA; ESEMeD/MHEDEA 2000 investigators (2008) Mediators of the
11. Association between depression and role functioning. Acta PsychiatrScand 118:451–458.
12. Jaeger J, Berns S, Uzelac S, Davis-Conway S (2006) Neurocognitive deficits and disability in
13. Major depressive disorder. Psychiatry Res 2006 Nov 29;145(1):39-48. doi:

14. Greer TL, Kurian BT, Trivedi MH (2010) Defining and measuring functional recovery from
15. Depression. CNS Drugs 2010 Apr;24(4):267-84.

16. Greenberg P.E, Forurnier AA, SistskyT,Pike CT, Kessler RC,(2015). The economic burden of
17. Adults with Major Depressive Disorder in the United States (2005-2010). The Journal of
18. Clinical Psychiatry;76(2):155-165.
19. Porter RJ, Bourke C, Gallagher P (2007) Neuropsychological impairment in major depression:
20. Its nature, origin and clinical significance. Aust NZ J Psychiatry 41:115–128.
21. Hammar A, Ardal G (2009) Cognitive functioning in major depression – a summary. Front Hum
22. Neurosci 3:26. doi: 10.3389/neuro.09.026.2009.
23. Katona C, Hansen T, Olsen CK (2012) A randomized, doubleblind, placebo-controlled,
24. Duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004
25. In elderly patients with major depressive disorder. Int Clin Psychopharmacol 27:215–223.
26. Biringer E, Rongve A, Lund A (2009) A review of modern antidepressants’ effects on
27. Neurocognitive function. Curr Psych Rev 5:164–174

28. McIntyre RS, Cha DS, Soczynska JK, Woldeyohannes HO, Gallaugher LA, Kudlow P,
29. Alsuwaidan M, Baskaran A (2013) Cognitive deficits and functional outcomes in major
30. Depressive disorder: determinants, substrates, and treatment interventions. Depression
31. Anxiety 30:515–527.
32. Raskin J, Wiltse CG, Siegal A, Sheikh J, Xu J, Dinkel JJ, Rotz BT, Mohs RC (2007) Efficacy of Duloxetine on cognition, depression, and pain in elderly patients with major depressiveDisorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 164:900–909.

33. Rund BR, Sundet K, Asbjornsen A, Egeland J, Landro NI, Lund A, Roness A, Stordal KI,
34. Hugdahl K (2006) Neuropsychological test profiles in schizophrenia and nonpsychotic
35. Depression. Acta PsychiatrScand 113:350–3.
36. Lee RS, Hermens DF, Porter MA, Redoblado-Hodge MA (2012) A meta-analysis of cognitive
37. Deficits in first-episode Major Depressive Disorder. J Affect Disord 140:113–124.
38. Rock PL, Roiser JP, Riedel WJ, Blackwell AD (2013) Cognitive impairment in depression: a
39. Systematic review and meta-analysis. Psychol Med 1–12. doi: 10.1017/
40. S0033291713002535.
41. Harmer CJ, Bhagwagar Z, Cowen PJ, Goodwin GM (2002) Acute administration of citalopram
42. Facilitates memory consolidation in healthy volunteers. Psychopharmacology (Berl)
43. 163:106–110
44. Campbell S, Macqueen G (2004) The role of the hippocampus in the pathophysiology of major
45. Depression. J Psychiatry Neurosci 29:417–426.
46. Murrough JW, Henry S, Hu J, Gallezot JD, Planeta-Wilson B, Neumaier JF, Neumeister A
47. (2011) Reduced ventral striatal/ ventral pallidal serotonin1B receptor binding potential in
48. Major depressive disorder. Psychopharmacology (Berl) 213:547–553.
49. Zimmerman M, Martinez J, Attiullah N, Friedman M, Toba C, Boerescu DA (2012) Why do
50. Some depressed outpatients who are not in remission according to the Hamilton depression
51. Rating scale nonetheless consider themselves to be in remission? Depress Anxiety 29:891–
52. 895.
53. Minhas F, Rana R, Rana M, Hamdani S. Perceived Cognitive Dysfunction in Patients with Major Depressive Disorder in Pakistan: A Cross-Sectional Study [Internet]. Jpps.com.pk. 2019 http://www.jpps.com.pk/article/perceivedcognitivedysfunctioninpatientswithmajordepressivedisorderinpakistanacrosssectionalstudy_2686.html
Published
2023-12-30
How to Cite
1.
Mufti AA, Huma Mughal, Mukhtar Ul Haq Azeemi, Muhammad Asif Kamal, Fazale Rabbani, Khalid Attaullah Mufti, Syed Muhammad Sultan, Bashir Ahmad, Zainab Nawaz, Adil Afridi, Fatima Amir Khan, Muhammmad Fahim Qasim, Shakil Asif, Syed Usman Hamdani, Ayesha Minhas, FAREED ASLAM MINHAS. PREVIDA- IMPACT OF VORTIOXETINE ON MAJOR DEPRESSIVE DISORDER AND PERCEIVED COGNITIVE DYSFUNCTION- A MULTICENTER STUDY. J Pak Psychiatr Soc [Internet]. 2023Dec.30 [cited 2024Apr.27];20(04). Available from: https://jpps.pk/index.php/journal/article/view/281
Issue
Vol 20 No 04 (2023): Journal of Pakistan Psychiatric Society
Section
Articles

Copyright

Copyright (c) 2024. Authors.

Licencing

  

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purposes. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.